Medical World News® Inside the Practice: CancerNetwork® and Albert H. Kim, MD, PhD, on Treating Brain Tumor Malignancies at the Siteman Cancer Center

Video

CancerNetwork® spoke with Albert H. Kim, MD, PhD, about a new Brain Tumor Center at Siteman, for which he is the inaugural director.

For the latest installment of the Inside the Practice segment of the Medical World News® broadcast, CancerNetwork® spoke with Albert H. Kim, MD, PhD, of the Washington University School of Medicine and Barnes-Jewish Hospital, about the newly established Brain Tumor Center at the Siteman Cancer Center. The center will bring together multidisciplinary specialists in neurosurgery, medicine, radiation oncology, pathology, immunology, otolaryngology, and endocrinology to conduct cutting-edge research

In the interview, Kim talked about a new neuroscience building on the medical campus that will eventually house the center as well as 100 or so laboratories for clinical research.

The center also offers some leading-edge treatment techniques, like proton beam therapy for malignancies in adult and pediatric patients, that may offer options not yet available at other institutions.

This segment comes from the CancerNetwork® portion of the MJH Life Sciences™ Medical World News®, airing daily on all MJH Life Sciences™ channels.

Related Videos
ZAP-X may provide submillimeter accuracy when administering radiation to patients with brain tumors.
It takes a team of physicians from multidisciplinary backgrounds to best manage patients with contralateral breast cancer, according to a Mayo Clinic Expert.
The presence of several risk factors—such as age, race and mutation status—for contralateral breast cancer must be considered when making treatment decisions, according to an expert from the Mayo Clinic.
Recent study findings related to risk factors for developing contralateral breast cancer may better influence treatment decisions between patients and physicians, according to a Mayo Clinic expert.
An expert from the Mayo Clinic discusses findings from a population-based study concerning germline genetic mutations as risk factors of contralateral breast cancer.
Thus far, findings from 2 trials show that treatment with bipolar androgen therapy is associated with several benefits in patients with castration-resistant prostate cancer, according to an expert from Sidney Kimmel Comprehensive Cancer Center.
An expert from the Mayo Clinic explains why he and his colleagues are researching risk factors for contralateral breast cancer in carriers of moderate-risk genes such as ATM, CHEK2, and PALB2.
Investigators have observed that treatment with bipolar androgen therapy has suppressed at least one oncogene in patients with castration-resistant prostate cancer who derived a response to therapy.
Despite the observed disease-free survival benefit associated with pembrolizumab in high-risk kidney cancer after surgery, the European Association of Urology guidelines maintain a weak recommendation for its use.
Don Dizon, MD, FACP, FASCO, describes the importance of establishing a gender-affirming environment for patients with cancer.
Related Content
The FDA approval of the single-agent, oral pan-RAF inhibitor tovorafenib is based on efficacy results from the phase 2 FIREFLY-1 trial.

FDA Approves Tovorafenib for Relapsed/Refractory Low-Grade Glioma

April 23rd 2024
Article

The FDA approval of the single-agent, oral pan-RAF inhibitor tovorafenib is based on efficacy results from the phase 2 FIREFLY-1 trial.

Javier Orozco-Mera, MD, FACS, MSc, discusses signaling pathways and molecular mechanisms involved in the relapse of glioblastoma.

Oncology-On-The-Go Podcast: Signaling Pathways in Glioblastoma Relapse

May 1st 2023
Podcast

Javier Orozco-Mera, MD, FACS, MSc, discusses signaling pathways and molecular mechanisms involved in the relapse of glioblastoma.

First-in-patient findings support AZD1390 as a potential radiosensitizer during the management of glioblastoma.

AZD1390/Radiation Yields Encouraging Efficacy, Safety in Glioblastoma

April 9th 2024
Article

First-in-patient findings support AZD1390 as a potential radiosensitizer during the management of glioblastoma.

Promising Glioma Therapy Options

Promising Glioma Therapy Options

December 21st 2018
Podcast

Dr. James Perry speaks with Cancer Network about glioma therapy options and the future of brain cancer treatment.

Findings from a phase 1b trial support the tolerability and potential survival benefit of CAN-3110 as a treatment for patients with recurrent high-grade glioma.

CAN-3110 Earns FDA Fast Track Designation in Recurrent High-Grade Glioma

February 13th 2024
Article

Findings from a phase 1b trial support the tolerability and potential survival benefit of CAN-3110 as a treatment for patients with recurrent high-grade glioma.

Eflornithine, which was approved in adult and pediatric patients with high-risk neuroblastoma, was assessed in an externally controlled trial comparing results in both Study 3b and Study ANBL0032.

Eflornithine Is Approved by the FDA for High-Risk Neuroblastoma

December 13th 2023
Article

Eflornithine, which was approved in adult and pediatric patients with high-risk neuroblastoma, was assessed in an externally controlled trial comparing results from Study 3b and Study ANBL0032.